Account-level · SKU-level · Traditional trade

    Pharmaceutical competitor intelligence — brand vs competitors in-market

    Last updated 6 September 2026 · Armela Belba

    Pharmaceutical competitor intelligence is primary evidence of how a named brand stacks up against named competitors in a named country — at account level and SKU level, including traditional trade the syndicated feed does not cut. BioNixus fields that study so a local affiliate can fill the competitive slide IQVIA cannot populate. Proposal within 48 hours of a brief.

    Request a competitor study

    Primary research, market access & HEOR. Proposals within 48 hours.

    Pharmaceutical competitor intelligence — brand vs competitors in-market

    Pharmaceutical competitor intelligence is primary evidence of how a named brand stacks up against named competitors in a named country — at account level and SKU level, including traditional trade the syndicated feed does not cut. BioNixus fields that study so a local affiliate can fill the competitive slide IQVIA cannot populate. Proposal within 48 hours of a brief.

    • When syndicated is enoughKeep IQVIA for national share of market. Keep Kantar when the question is brand equity on a global tracker. Those products are not account-level competitor intelligence.
    • When to brief BioNixusBrief this study when the Head of Marketing and Commercial Director need brand versus competitors in specific hospitals, pharmacies, or distributors — or when a launch, a competitor entry, or a lost QBR created the gap.
    • Coverage48 countries. Local field teams. Account-level and SKU-level cuts. 48 hours from brief to proposal.

    Pharmaceutical competitor intelligence is primary evidence of how a named brand stacks up against named competitors in a named country — at account level and SKU level, including traditional trade the syndicated feed does not cut. BioNixus fields that study so a local affiliate can fill the competitive slide IQVIA cannot populate. Proposal within 48 hours of a brief.

    When IQVIA is enough vs when to brief this study

    Keep the syndicated feed

    Keep IQVIA for national share of market. Keep Kantar when the question is brand equity on a global tracker. Those products are not account-level competitor intelligence.

    Brief BioNixus

    Brief this study when the Head of Marketing and Commercial Director need brand versus competitors in specific hospitals, pharmacies, or distributors — or when a launch, a competitor entry, or a lost QBR created the gap.

    Read IQVIA alternative and what account-level data is. Country vendor shortlists stay on the listicles — this page owns the study type.

    Egypt, UAE, and Saudi Arabia

    Pharmaceutical competitor intelligence in Egypt

    Brand versus competitors across Cairo, Alexandria, and Upper Egypt accounts — EDA context, bilingual fieldwork. The Egypt listicle is the vendor shortlist; this page is the study.

    Competitor intelligence in the UAE

    Account- and SKU-level brand versus competitor work across emirates. Keep IQVIA for the audit; brief BioNixus when the affiliate needs named accounts.

    Competitor intelligence in Saudi Arabia

    How this brand stacks up in named KSA accounts — hospitals, chains, traditional trade — with SFDA and NUPCO context. GCC hospital and payer depth is a BioNixus proof point.

    Request a competitor study

    Primary research, market access & HEOR. Proposals within 48 hours.

    Frequently asked questions

    What is pharmaceutical competitor intelligence at account level?

    It is brand-versus-competitor evidence cut by named customer account and SKU in a named country — not a national average. That is the language affiliates use in the brief.

    Do we still need IQVIA?

    Usually yes. IQVIA sizes the category. This study explains the accounts and SKUs the feed cannot cut. BioNixus is the complement, not a replacement.

    What methods do you use?

    HCP interviews and surveys, pharmacy and hospital pulls, mystery shopping where availability is the question, and desk synthesis only as support — never as the account-level source.

    Can KOL mapping or message testing sit on the same brief?

    Yes as modules on this study, until those queries earn their own URLs. Say so in the brief; do not expect a separate ranking page.

    Related

    Healthcare market research companies

    Who to brief for primary vs syndicated work.

    Pharmaceutical market research company

    Custom primary provider vs IQVIA data platform.

    IQVIA alternative

    Keep the audit. Brief fieldwork when the cut stops at national.

    Account-level data

    Named hospital, retailer, or distributor — not a country total.

    Healthcare MR companies UAE

    Custom primary firm for Dubai and Abu Dhabi affiliates.

    Healthcare MR companies KSA

    SFDA-aware primary research vs syndicated audits.

    Market research companies Egypt

    Cairo, Alexandria, and Upper Egypt fieldwork.

    Pricing bands

    Project- and country-based 2026 ranges.